{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T21:58:06Z","timestamp":1784757486436,"version":"3.55.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Hyperuricemia and gout are associated with poor outcomes in kidney transplant (KT) recipients, including graft failure. The PROspective sTudy of pEglotiCase in Transplant patients (PROTECT) trial showed high urate-lowering efficacy of pegloticase in immunosuppressed KT recipients with uncontrolled gout. Here, we report serial dual-energy computed tomography (DECT) findings in PROTECT participants.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>KT recipients with uncontrolled gout (serum urate [SU] \u22657\u2009mg\/dL, refractory to\/intolerant of oral urate-lowering therapy, and symptoms [\u22652 flares per year, tophi, and\/or gouty arthritis]) and serial DECT imaging were included. Patients were required to have an estimated glomerular filtration rate \u226515\u2009mL\/min\/1.73 m<jats:sup>2<\/jats:sup> &gt;1 y posttransplant. All patients received pegloticase for \u226424\u2009wk (8\u2009mg infusion every 2 wk) and underwent imaging (screening, week 14, week 24). DECT images were acquired with standard protocols and postprocessed for monosodium urate (MSU) volume (V<jats:sub>MSU<\/jats:sub>) using default settings. Regions (bilateral hands\/wrists, feet\/ankles, knees) with paired screening\/week 24 images and screening V<jats:sub>MSU<\/jats:sub> \u22650.5\u2009cm<jats:sup>3<\/jats:sup> (minimized DECT-artifact influence) were included.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>Eight patients underwent DECT imaging (all men; age: 52.3\u2005\u00b1\u200511.2 y, time since KT: 18.7\u2005\u00b1\u20056.9 y, estimated glomerular filtration rate: 45.6\u2005\u00b1\u200512.4\u2009mL\/min\/1.73 m<jats:sup>2<\/jats:sup>, SU: 10.4\u2005\u00b1\u20052.1\u2009mg\/dL). Six patients (75%) completed the study and received 24\u2009wk of pegloticase therapy, and 2 prematurely discontinued because of COVID-exposure concerns. Of the 6 patients, 4 met imaging inclusion criteria and were included in the analysis. All 4 patients had sustained SU-lowering during month 6 with marked V<jats:sub>MSU<\/jats:sub> reduction at week 24 (mean change in V<jats:sub>MSU<\/jats:sub>: \u201398.9%\u00b11.7% [5 imaging regions]). Numerous bone erosions were present in all patients with MSU-adjacent, unknown mineral deposit-adjacent, and deposit-independent erosions. Imaging suggested osteopenia\/osteomalacia in 5 patients (83%). After pegloticase treatment, MSU-adjacent erosions decreased in size in a single patient with no DECT evidence of osteopenia\/osteomalacia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>Consistent with prior studies in nontransplant populations, marked depletion of deposited MSU occurred in KT recipients with uncontrolled gout after pegloticase therapy. However, unlike transplant-naive patients, subsequent bone erosion remodeling was not widely observed in urate-adjacent erosions, perhaps due to overall poor bone health in this patient population.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical Trial Registration.<\/jats:title>\n            <jats:p>ClinicalTrials.gov: NCT04087720.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/txd.0000000000001803","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:07Z","timestamp":1747094407000},"page":"e1803","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Monosodium Urate Crystal Depletion and Bone Erosion Response in Kidney Transplant Recipients With Uncontrolled Gout Treated With Pegloticase: PROTECT Serial Dual-Energy Computed Tomography Findings"],"prefix":"10.1097","volume":"11","author":[{"given":"Nicola","family":"Dalbeth","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Auckland, Auckland, New Zealand."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Abdellatif","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Kidney Hypertension Transplant Clinic, Baylor College of Medicine, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Botson","sequence":"additional","affiliation":[{"name":"Orthopedic Physicians Alaska, Anchorage, AK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth G.","family":"Saag","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Kumar","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lissa","family":"Padnick-Silver","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zana","family":"Vranic","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad A.","family":"Marder","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Becce","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"R1-20250512","doi-asserted-by":"crossref","first-page":"292","DOI":"10.18433\/jpps31620","article-title":"The impact of hyperuricemia on long-term clinical outcomes of renal transplant recipients: a systematic review and meta-analysis.","volume":"24","author":"Yang","year":"2021","journal-title":"J Pharm Pharm Sci"},{"key":"R2-20250512","doi-asserted-by":"crossref","first-page":"e634","DOI":"10.1097\/TXD.0000000000001081","article-title":"New-onset gout as an independent risk factor for returning to dialysis after kidney transplantation.","volume":"6","author":"Li","year":"2020","journal-title":"Transplant Direct"},{"key":"R3-20250512","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1016\/j.transproceed.2019.08.037","article-title":"Prevalence of gout in the surviving United States solid organ transplantation population.","volume":"51","author":"Brigham","year":"2019","journal-title":"Transplant Proc"},{"key":"R4-20250512","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.2165\/00003495-200565180-00004","article-title":"Gout in solid organ transplantation: a challenging clinical problem.","volume":"65","author":"Stamp","year":"2005","journal-title":"Drugs"},{"key":"R5-20250512","doi-asserted-by":"crossref","first-page":"956213","DOI":"10.3389\/fsurg.2022.956213","article-title":"Risk factors and management of hyperuricemia after renal transplantation.","volume":"9","author":"Zi","year":"2023","journal-title":"Front Surg"},{"key":"R6-20250512","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1093\/rheumatology\/keac173","article-title":"Dual-energy CT assessment of rapid monosodium urate depletion and bone erosion remodelling during pegloticase plus methotrexate co-therapy.","volume":"61","author":"Dalbeth","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R7-20250512","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1136\/annrheumdis-2013-204273","article-title":"Relationship between structural joint damage and urate deposition in gout: a plain radiography and dual-energy CT study.","volume":"74","author":"Dalbeth","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R8-20250512","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1136\/ard.2010.144774","article-title":"Monosodium urate monohydrate crystals inhibit osteoblast viability and function: implications for development of bone erosion in gout.","volume":"70","author":"Chhana","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R9-20250512","doi-asserted-by":"crossref","first-page":"105715","DOI":"10.1016\/j.jbspin.2024.105715","article-title":"Examination of monosodium urate crystal depletion and bone erosion remodeling during pegloticase treatment in patients with uncontrolled gout: exploratory dual-energy computed tomography findings from MIRROR RCT.","volume":"91","author":"Dalbeth","year":"2024","journal-title":"Joint Bone Spine"},{"key":"R10-20250512","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.2215\/CJN.11371015","article-title":"Bone disease after kidney transplantation.","volume":"11","author":"Bouquegneau","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"R11-20250512","first-page":"77","article-title":"Prevalence and influence of gout in patients with advanced 2 chronic kidney disease: findings of a large retrospective chart review.","volume":"2","author":"Stern","year":"2024","journal-title":"Gout Urate Cryst Dep Dis"},{"key":"R12-20250512","doi-asserted-by":"crossref","first-page":"e14993","DOI":"10.1111\/ctr.14993","article-title":"Pegloticase efficacy and safety in kidney transplant recipients; results of the phase IV, open-label PROTECT clinical trial.","volume":"37","author":"Abdellatif","year":"2023","journal-title":"Clin Transplant"},{"key":"R13-20250512","doi-asserted-by":"crossref","first-page":"1516146","DOI":"10.3389\/fimmu.2025.1516146","article-title":"Quality of life improvements and clinical assessments in kidney transplant recipients undergoing pegloticase treatment for uncontrolled gout: findings of the phase 4 PROTECT clinical trial.","volume":"16","author":"Abdellatif","year":"2025","journal-title":"Front Immunol"},{"key":"R14-20250512","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2214\/AJR.14.13901","article-title":"Getting the most from your dual-energy scanner: recognizing, reducing, and eliminating artifacts.","volume":"206","author":"Coupal","year":"2016","journal-title":"AJR Am J Roentgenol"},{"key":"R15-20250512","doi-asserted-by":"crossref","first-page":"e18431","DOI":"10.1097\/MD.0000000000018431","article-title":"Relationship between urate within tophus and bone erosion according to the anatomic location of urate deposition in gout: a quantitative analysis using dual-energy CT volume measurements.","volume":"98","author":"Shi","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"R16-20250512","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/art.41509","article-title":"Repair of bone erosion with effective urate-lowering therapy in a patient with tophaceous gout.","volume":"73","author":"Sakaguchi","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R17-20250512","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1007\/s11255-022-03116-5","article-title":"Hyperuricemia is associated with secondary hyperparathyroidism in patients with chronic kidney disease.","volume":"54","author":"Costa","year":"2022","journal-title":"Int Urol Nephrol"},{"key":"R18-20250512","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3390\/gucdd2010008","article-title":"Prevalence and influence of gout in patients with advanced chronic kidney disease: findings of a large retrospective chart review.","volume":"2","author":"Stern","year":"2024","journal-title":"Gout Urate Cryst Depos Dis"}],"container-title":["Transplantation Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001803","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:11Z","timestamp":1747094411000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/txd.0000000000001803","relation":{},"ISSN":["2373-8731"],"issn-type":[{"value":"2373-8731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]}}}